Cyanoacrylate tissue adhesives
A tissue adhesive including cyanoacrylate and polyethylene glycol (PEG), wherein the PEG remains a polyether and wherein the tissue adhesive is bioabsorbable. A tissue adhesive including cyanoacrylate bulk monomer and cyanoacrylate nanoparticles containing a therapeutic therein. A kit for applying tissue adhesive, including the tissue adhesive described above and an applicator. Methods of accelerating degradation of a cyanoacrylate tissue adhesive applying a tissue adhesive, closing an internal wound, administering a therapeutic to tissue, treating cancer, and preventing infection in a wound. Methods of method of making a bioabsorbable tissue adhesive and making a therapeutic tissue adhesive.
1. A composition, comprising:
a tissue adhesive having:
a cyanoacrylate monomer selected from the group consisting of methoxyisopropylcyanoacrylate, octylcyanoacrylate, and methoxyisopropylcyanoacrylate; and
polyethylene glycol (PEG) that remains a polyether in the adhesive, and
polymerized cyanoacrylate nanoparticles containing an effective amount of a therapeutic agent,
wherein said nanoparticles are homogenously mixed together and miscible with the adhesive, and, when mixed together with the adhesive, remain miscible in the adhesive and do not initiate polymerization of the cyanoacrylate monomer.
2. The tissue adhesive composition of claim 1 , wherein said therapeutic agent is selected from the group consisting of antibacterial agents, antifungal agents, anticancer agents, and anti-inflammatory drugs.
3. The tissue adhesive composition of claim 2 , wherein said therapeutic agent is an antibacterial agent selected from the group consisting of polymyxin B sulfate, neomycin sulfate, gentamycin sulfate, gramicidin, zinc bacitracin, and hydroxyquinolone.
4. The tissue adhesive composition of claim 2 , wherein said therapeutic agent is an antifungal agent selected from the group consisting of terbinafine, clotrimazole, ketokonazole, nystatin, and amphotericin B.
5. The tissue adhesive composition of claim 2 , wherein said therapeutic agent is an anticancer agent selected from the group consisting of 5-fluorouracil, doxorubicin, and paclitaxel.
6. The tissue adhesive composition of claim 2 , wherein said therapeutic agent is an anti-inflammatory agent selected from the group consisting of ibuprofen, ketoprofen, dexamethasone, and predisolone.
7. The tissue adhesive composition of claim 1 , wherein said composition is formulated in a patch.
8. The tissue adhesive composition of claim 7 , wherein said composition is formulated in a patch and said therapeutic agent is chosen from the group consisting of nicotine and glucose.
9. The tissue adhesive composition of claim 1 , wherein the tissue adhesive composition is bioabsorbed within 12 weeks when applied to an internal tissue of a wound or incision.